Skip to main content

Advertisement

SpringerLink
Log in

Stem-cell discovery platforms yield first clinical candidates

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Induced pluripotent stem cell-derived 'disease-in-a-dish' models have propelled neurological drugs from Bristol-Myers Squibb, GlaxoSmithKline and Roche into clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Stem-cell discovery platforms yield first clinical candidates. Nat Rev Drug Discov 14, 589–591 (2015). https://doi.org/10.1038/nrd4708

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4708

  • Springer Nature Limited

This article is cited by

Search

Navigation